Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Teleflex (TFX)

Teleflex raises 2025 EPS guidance as Q2 GAAP diluted EPS rises to $2.77

Positive Impact 4 of 5 earnings Written later

Teleflex reported second-quarter 2025 GAAP revenue of $780.9 million, up 4.2% from a year earlier, and GAAP diluted EPS from continuing operations of $2.77, compared with $1.69. The company raised its full-year 2025 guidance, which it says includes the BIOTRONIK Vascular Intervention business acquired at the start of the third quarter. Management said underlying adjusted constant currency revenue guidance, excluding the acquisition, is unchanged.

Key points

  • Adjusted diluted EPS from continuing operations was $3.73, compared with $3.42 in the prior year period; adjusted constant currency revenue growth was 1.0%.
  • 2025 GAAP diluted EPS from continuing operations guidance was raised to $6.73 to $7.13, from $6.51 to $6.91.
  • 2025 adjusted diluted EPS guidance was raised to $13.90 to $14.30, from $13.20 to $13.60.
  • The acquired BIOTRONIK business is expected to generate $204 million of revenue in the second half of 2025.

The filing

CompanyTeleflex (TFX)
Form8-K, current report
Filed with the SECJul 31, 2025, 7:00 AM ET
Accession number0000096943-25-000112

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.